NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ADVANCED HUMAN IMAGING LTD (AHI)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
ADVANCED HEALTH INTELLIGENCE LTD14/12/2022
ADVANCED HUMAN IMAGING LTD11/03/202114/12/2022
MYFIZIQ LIMITED11/03/2021

Shareholder links

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000MYQ4
Address: Suite 8, 7 The Esplanade, MT PLEASANT, WA, AUSTRALIA, 6153
Tel:  08 9316 9100

Date first listed: 17/08/2015
Company Secretary: Simon Durack
Sector: Software & Services Industry Group: XIJ

News & Events

Expand this box to read and print

name changed to Advanced Health Intelligence Ltd

14/12/2022

The suspension of trading in the securities of Advanced Human Imaging Ltd will be lifted from the commencement of trading on Friday, 14 October 2022 following lodgement of its Audited Financial Statement for the period ended 30 June 2022.

13/10/2022

The company lodges its annual report. In the preliminary final report and Appendix 4E for the financial year ended 30 June 2022, released on 1 September 2022, the company reported an unaudited net loss after tax of $20,572,729. During the course of the audit, it was determined that the company had incorrectly accounted for some of its non-cash share based payments during the course of the year, which when corrected increased the company's audited net loss after tax from $20,572,729 to $22,641,925 for the year ended 30 June 2022.

13/10/2022

The Company will not be lodging its 2022 financial statements until 12 October 2022. This further delay has been necessary to ensure that all new and existing audit requirements have been completed and will form the basis for the required reporting in the United States of America, following the Company's successful listing on NASDAQ.

11/10/2022

The securities of the company will be suspended from Official Quotation in accordance with Listing Rule 17.5 from the commencement of trading today, 3 October 2022, following their failure to lodge the relevant periodic report by the due date.

03/10/2022

There will be a delay in the lodgement of the Company's Financial Statements for the year ended 30 June 2022. The delay is to allow the Company to complete all the requirements of its newly appointed Auditor, PKF Brisbane Audit.

03/10/2022

The suspension of trading in the securities of Advanced Human Imaging Ltd will be lifted from the commencement of trading on Friday, 2 September 2022, following the release by AHI of an announcement regarding a material acquisition and a response to an ASX Price Query.

02/09/2022

The company has entered into a definitive arrangement agreement with wellteq Digital Health Inc. whereby AHI will acquire all of the outstanding shares of wellteq in an all-share acquisition. wellteq shareholders will receive one (1) ordinary share of AHI for every six (6) wellteq common shares held (or 0.1667 AHI Shares for every 1 wellteq Share). AHI will issue a total of approximately 17,811,508 AHI shares in total consideration for 100% of wellteq's shares. Following completion of the Transaction, wellteq shareholders in aggregate will hold approximately 9.573% of AHI's issued capital.

02/09/2022

The company issues a response to ASX Price Query.

02/09/2022

The securities of Advanced Human Imaging will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHI, pending the release of an announcement regarding a material acquisition and a response to an ASX Price Query.

01/09/2022

The suspension of trading in the securities of Advanced Human Imaging Ltd will to be lifted immediately following the release by AHI of an announcement regarding the Company's recently completed Nasdaq capital raising.

24/11/2021

The company issued a notice of proposed issue of securities.

24/11/2021

The company's convertible note subscription agreements with Asia Cornerstone Asset Management ) and iConcept Global Growth Fund have been settled by mutual agreement. The Company has agreed to issue 2,271,834 fully paid ordinary shares represented by American Depository Shares to ACAM and 738,576 ADSs to iCGGF in full and final settlement of all claims under or in connection with the Agreements.

24/11/2021

The company's previously announced U.S. initial public offering of 1,000,000 units at a price to the public of US$10.50 per unit has closed. t. Each unit issued in the offering consisted of two American Depositary Shares and one warrant to purchase one ADS. Each ADS offered represented 7 ordinary shares of AHI. The warrants were exercisable immediately, expire three years from the date of issuance and have an exercise price of US$5.52 per ADS. The ADSs and warrants were immediately separable and were issued separately. , AHI granted to Maxim Group LLC a 45-day option to purchase up to an additional 300,000 ADSs and/or up to an additional 150,000 warrants to purchase up to 150,000 ADSs, at the public offering price less underwriting discounts, of which Maxim Group LLC has partially exercised its option to purchase such 150,000 warrants to purchase up to 150,000 ADSs.

24/11/2021

The securities of Advanced Human Imaging Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHI, pending the release of an announcement in connection with the Company's recently completed Nasdaq capital raising.

22/11/2021

The suspension of trading in the securities of Advanced Human Imaging Ltd will be lifted from the commencement of trading on Monday, 19 April 2021, following the receipt of a response to an ASX Price and Volume Query.

19/04/2021

The company releases a response to ASX price and volume query.

19/04/2021

AHI has concluded all required due diligence required under the Binding term sheet. AHI has now executed all formal agreements with Triage Technologies. AHI to implement Triage's Artificial Intelligence "health assistant" technology within the CompleteScan SaaS offering. Triage AI technology platform can currently identify 588 skin conditions in 133 major categories via smartphone and is currently available in 200 countries around the world. The Triage AI platform has been used over 600,000 times since launch in late 2019. Advanced Human Imaging will also take a strategic equity stake in Triage.

19/04/2021

Physimax has developed Advanced Musculoskeletal Assessment Artificial Intelligence. Musculoskeletal conditions affect 1.71 billion people worldwide. Musculoskeletal disorders such as lower back pain cause the highest burden on healthcare systems with a prevalence of 568 million people worldwide. Musculoskeletal conditions are the leading contributor to disability worldwide, causing disability in 160 countries. Musculoskeletal conditions significantly limit mobility and dexterity, leading to early retirement from work, lower levels of well-being and reduced ability to participate in society. Due to population increases and ageing, the number of people with musculoskeletal conditions is rapidly increasing. The disability associated with musculoskeletal conditions has been increasing and is projected to continue to increase in the next decade. $16 billion lost annually from Australian GDP due to Musculoskeletal conditions. Physimax is chosen by clinicians, elite sports teams, and the US Military.

19/04/2021

The suspension of the company's securities is expected to last until the earlier of the company finalising the response and announcement in relation to the material potential acquisition or commencement of trade on 20 April 2021.

13/04/2021

The suspension of the company's securities is expected to last until the earlier of the company finalising the response and announcement regarding the company's response to ASX's price and volume query letter and an announcement in relation to a material potential acquisition, or commencement of trade on 13 April 2021.

06/04/2021

The securities of Advanced Human Imaging Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHI, pending the Company's response to ASX's price query letter dated 30 March 2021.

01/04/2021

name changed from MyFiziq Limited

11/03/2021

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    04/07/2019Peter Wall200,000$0.172$34,315
    19/06/2017Vlado Bosanac18,440$0.068$1,253
    09/06/2017Vlado Bosanac133,424$0.068$9,102
    02/03/2017Peter Wall1,000,000$0.046$45,895

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Vlado BosanacExecutive Chairman, CEO17/10/2016
    Simon DurackCFO17/03/2022
    Jacqueline YeeIndependent Director20/12/2022
    Peter GoldsteinNon Exec Director29/06/2022
    Dato LowNon Exec Director13/07/2020
    Luisa IngargiolaNon Exec Director26/02/2021
    Mike MelbyNon Exec Director27/10/2017
    Nick ProsserNon Exec Director18/04/2018
    Scott MontgomeryExecutive Director, CEO01/12/2022
    Katherine IscoeExecutive Director17/08/2015

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Peter W. VaughanNon Exec Director01/12/202216/12/2022
    Edward Greissing Jr.Non Exec Director30/11/202126/05/2022
    Steven RichardsCFO02/09/201917/03/2022
    Peter WallNon Exec Chairman, CEO17/08/201522/01/2021
    Cyril DonnellyNon Exec Director17/08/201531/07/2017
    Evan CrossFinance Director17/08/201531/10/2016

    Date of first appointment, title may have changed.